Login to Your Account



2012 Year in Review

Phase II Assets Gained Value, but Deals Lagged

By Marie Powers
Staff Writer

Wednesday, January 23, 2013
A Deloitte Recap LLC analysis of 2012 biopharma dealmaking activity suggested a seller's market for Phase II assets, with median up-front cash of $35 million for market rights in transactions involving at least one major territory, up from a median of $30 million during the 2007-2011 time frame. However, market rights at other stages, including approval, lagged, as did the total deal flow.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription